9th August 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

Charak Pharma set to release Fortyfitt Woman tablets

Vedistry, a division of Charak Pharma, has announced the release of Fortyfitt Woman Tablets, a nutritional supplement that assists women in their forties with a smooth transition from perimenopause to menopause and overall health.

Pfizer to pay $5.4 billion for Global Blood Therapeutics, a biopharma company

Pfizer will acquire Global Blood Therapeutics, a biopharmaceutical company committed to the discovery, development, and delivery of life changing treatments that bring support to underserved patient communities, starting with sickle cell disease.

Alembic Pharma subsidiary receives USFDA approval for Topical Adapalene & Benzoyl Peroxide gel

Alembic Pharmaceuticals announced that its wholly-owned subsidiary Aleor Dermaceuticals has received final approval from the US Food and Drug Administration for its generic version of a topical gel used to treat acne vulgaris.

Swiss pharma company provides Rs 16-crore drug to save 23-month-old Hyderabad baby

A 23-month-old baby with Spinal Muscular Atrophy-1 (SMA-1), a rare genetic disorder, was given Zolgensma Gene Therapy, the only treatment available, in the form of a Rs 16 crore injection supplied by Novartis.

Bayer's Nubeqa setto challenge Xtandi's prostate cancer crown with new approval

Nubeqa has been approved by the FDA to treat adults with metastatic hormone-sensitive prostate cancer. The green light allows Nubeqa to be used in advanced-stage prostate cancer as well as non-metastatic castration-resistant prostate cancer.

Bengaluru-based Eyestem raised $6.4 million in Series A round

Cell therapy company Eyestem, based in Bengaluru, has raised $6.4 million in Series A round led by three major pharmaceutical companies: Biological E Limited (BE), Alkem, NATCO, and Anurag and Karan Bagaria, Kemwell Biopharma’s promoters.

FDA approves Myovant & Pfizer's Myfembree for endometriosis after a delay

The label expansion for Myfembree’s use in endometriosis has been won by Myovant and Pfizer. Myfembree received its first FDA approval in May to treat heavy menstrual bleeding associated with uterine fibroids in premenopausal women. 

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?